Amount of qualified individuals: CDEC mentioned the uncertainty in the number of patients with reasonably critical to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some clients who're classified as having delicate or moderate disease can have a significant bleeding phenotype, https://israelcdecb.atualblog.com/42392194/facts-about-hemgenix-revealed